Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.

Saved in:
Bibliographic Details
Title: Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.
Authors: Pu T; Digestive Oncology, KU Leuven, Belgium., Peddle AM; Digestive Oncology, KU Leuven, Belgium., Wirapati P; Swiss Institute of Bioinformatics, Lausanne, Switzerland., Tsantoulis P; Geneva University Hospitals, Geneva, Switzerland., Wu Q; Digestive Oncology, KU Leuven, Belgium., Hong Y; Digestive Oncology, KU Leuven, Belgium., Samuel L; Oncology Department, School of Medicine, Medical Sciences and Nutrition, Aberdeen Royal Infirmary, University of Aberdeen, Aberdeen, UK., Desai J; Peter MacCallum Cancer Centre, Melbourne, Australia., Riener M; Docrates Syöpäsairaala, Helsinki, Finland., Saridaki Z; First Oncology Department, Metropolitan Hospital, Piraeus, Greece.; Asklepios, Oncology Department, Heraklion, Greece., Cunningham D; The Royal Marsden Hospital, London, UK., Tejpar S; Digestive Oncology, KU Leuven, Belgium. sabine.tejpar@uzleuven.be.
Source: NPJ precision oncology [NPJ Precis Oncol] 2026 Jan 13; Vol. 10 (1), pp. 50. Date of Electronic Publication: 2026 Jan 13.
Publication Type: Journal Article
Journal Info: Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2397-768X
DOI:10.1038/s41698-025-01253-5